Breast cancer lung metastasis: Molecular biology and therapeutic implications

References

• DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62. doi:10.3322/caac.21203. PMID:24114568.
   PubMed Web of Science ®Google Scholar
• Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147(2):275–92. doi:10.1016/j.cell.2011.09.024. PMID:22000009.
   PubMed Web of Science ®Google Scholar
• Eckhardt BL, Francis PA, Parker BS, Anderson RL. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov. 2012;11(6):479–97. doi:10.1038/nrd2372. PMID:22653217.
   PubMed Web of Science ®Google Scholar
• Cao H, Zhang Z, Zhao S, He X, Yu H, Yin Q, Zhang Z, Gu W, Chen L, Li Y. Hydrophobic interaction mediating self-assembled nanoparticles of succinobucol suppress lung metastasis of breast cancer by inhibition of VCAM-1 expression. J Control Release. 2015;205:162–71. doi:10.1016/j.jconrel.2015.01.015. PMID:25598420.
   PubMed Web of Science ®Google Scholar
• Pei S, Yang X, Wang H, Zhang H, Zhou B, Zhang D, Lin D. Plantamajoside, a potential anti-tumor herbal medicine inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of matrix metalloproteinase-9 and -2. BMC Cancer. 2015;15:965. doi:10.1186/s12885-015-1960-z. PMID:26674531.
   PubMed Web of Science ®Google Scholar
• Gaffan J, Dacre J, Jones A. Educating undergraduate medical students about oncology: a literature review. J Clin Oncol. 2006;24(12):1932–9. doi:10.1200/JCO.2005.02.6617. PMID:16622269.
   PubMed Web of Science ®Google Scholar
• Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-y period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005;104(8):1742–50. doi:10.1002/cncr.21359. PMID:16149088.
   PubMed Web of Science ®Google Scholar
• Gligorov J, Lotz JP. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2008;112 Suppl 1:53–66. doi:10.1007/s10549-008-0232-x. PMID:19101794.
   PubMedGoogle Scholar
• Smid M, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68(9):3108–14. doi:10.1158/0008-5472.CAN-07-5644. PMID:18451135.
   PubMed Web of Science ®Google Scholar
• Dan Z, Cao H, He X, Zhang Z, Zou L, Zeng L, Xu Y, Yin Q, Xu M, Zhong D, et al. A pH-responsive host-guest nanosystem loading succinobucol suppresses lung metastasis of breast cancer. Theranostics. 2016;6(3):435–45. doi:10.7150/thno.13896. PMID:26909117.
   PubMed Web of Science ®Google Scholar
• Liang Y, Xu X, Wang T, Li Y, You W, Fu J, Liu Y, Jin S, Ji Q, Zhao W, et al. The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis. Cell Death Dis. 2017;8(7):e2928. doi:10.1038/cddis.2017.325. PMID:28703807.
   PubMedGoogle Scholar
• Jensen TW, Ray T, Wang J, Li X, Naritoku WY, Han B, Bellafiore F, Bagaria SP, Qu A, Cui X, et al. Diagnosis of Basal-Like Breast Cancer Using a FOXC1-Based Assay. J Natl Cancer Inst. 2015;107(8). doi:10.1093/jnci/djv148..
   Google Scholar
• Ray PS, Wang J, Qu Y, Sim MS, Shamonki J, Bagaria SP, Ye X, Liu B, Elashoff D, Hoon DS, et al. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res. 2010;70(10):3870–6. doi:10.1158/0008-5472.CAN-09-4120. PMID:20406990.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012;21(3):242–52. doi:10.1016/j.breast.2012.03.003. PMID:22425534.
   PubMed Web of Science ®Google Scholar
• Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127(4):679–95. doi:10.1016/j.cell.2006.11.001. PMID:17110329.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-y survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717. doi:10.1016/S0140-6736(05)66544-0. PMID:15894097.
   PubMed Web of Science ®Google Scholar
• Soni A, Ren Z, Hameed O, Chanda D, Morgan CJ, Siegal GP, Wei S. Breast cancer subtypes predispose the site of distant metastases. Am J Clin Pathol. 2015;143(4):471–8. doi:10.1309/AJCPYO5FSV3UPEXS. PMID:25779997.
   PubMed Web of Science ®Google Scholar
• Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, Courdi A, Hannoun-Levi JM, Ettore F, Birtwisle-Peyrottes I, et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol. 2008;19(12):2012–9. doi:10.1093/annonc/mdn424. PMID:18641006.
   PubMed Web of Science ®Google Scholar
• Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer. 2003;97(3):545–53. doi:10.1002/cncr.11083. PMID:12548595.
   PubMed Web of Science ®Google Scholar
• Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271–7. doi:10.1200/JCO.2009.25.9820. PMID:20498394.
   PubMed Web of Science ®Google Scholar
• Bartmann C, Wischnewsky M, Stüber T, Stein R, Krockenberger M, Häusler S, Janni W, Kreienberg R, Blettner M, Schwentner L, et al. Pattern of metastatic spread and subcategories of breast cancer. Arch Gynecol Obstet. 2017;295(1):211–23. doi:10.1007/s00404-016-4225-4. PMID:27832352.
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48. doi:10.1056/NEJMra1001389. PMID:21067385.
   PubMed Web of Science ®Google Scholar
• Yhim HY, Han SW, Oh DY, Han W, Im SA, Kim TY, Kim YT, Noh DY, Chie EK, Ha SW, et al. Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy. Cancer. 2010;116(12):2890–901. doi:10.1002/cncr.25054. PMID:20564396.
   PubMed Web of Science ®Google Scholar
• Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Minisini AM, Fasola G, Puglisi F. Pattern of metastasis and outcome in patients with breast cancer. Clin Exp Metastasis. 2015;32(2):125–33. doi:10.1007/s10585-015-9697-2. PMID:25630269.
   PubMed Web of Science ®Google Scholar
• Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q, Wei W, Zhang Y, Sun S. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget. 2017. 8(17):27990–6. doi:10.18632/oncotarget.15856. PMID:28427196.
   PubMedGoogle Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–8. doi:10.1073/pnas.0530291100. PMID:12629218.
   PubMed Web of Science ®Google Scholar
• Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15(3):504–14. doi:10.1038/sj.cdd.4402283. PMID:18049477.
   PubMed Web of Science ®Google Scholar
• Czerwinska P, Kaminska B. Regulation of breast cancer stem cell features. Contemp Oncol (Pozn). 2015;19(1A):A7–A15. PMID:25691826.
   PubMedGoogle Scholar
• Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One. 2008;3(8):e2888. doi:10.1371/journal.pone.0002888. PMID:18682804.
   PubMed Web of Science ®Google Scholar
• Kotiyal S, Bhattacharya S. Breast cancer stem cells, EMT and therapeutic targets. Biochem Biophys Res Commun. 2014;453(1):112–6. doi:10.1016/j.bbrc.2014.09.069. PMID:25261721.
   PubMed Web of Science ®Google Scholar
• Langerod A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Ikdahl T, Kåresen R, Børresen-Dale AL, Jeffrey SS. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res. 2007;9(3):R30. doi:10.1186/bcr1675. PMID:17504517.
   PubMed Web of Science ®Google Scholar
• Schmitt F, Ricardo S, Vieira AF, Dionísio MR, Paredes J. Cancer stem cell markers in breast neoplasias: their relevance and distribution in distinct molecular subtypes. Virchows Arch. 2012;460(6):545–53. doi:10.1007/s00428-012-1237-8. PMID:22562130.
   PubMed Web of Science ®Google Scholar
• Chekhun SV, Zadvorny TV, Tymovska YO, Anikusko MF, Novak OE, Polishchuk LZ. capital ES, CyrillicD44+/CD24- markers of cancer stem cells in patients with breast cancer of different molecular subtypes. Exp Oncol. 2015;37(1):58–63. PMID:25804234.
   PubMedGoogle Scholar
• Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A, Hegardt C. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008. 10(3):R53. doi:10.1186/bcr2108. PMID:18559090.
   PubMed Web of Science ®Google Scholar
• Liu H, Patel MR, Prescher JA, Patsialou A, Qian D, Lin J, Wen S, Chang YF, Bachmann MH, Shimono Y, et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci U S A. 2010;107(42):18115–20. doi:10.1073/pnas.1006732107. PMID:20921380.
   PubMed Web of Science ®Google Scholar
• Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 2009;13(8B):2236–52. doi:10.1111/j.1582-4934.2008.00455.x. PMID:18681906.
   PubMed Web of Science ®Google Scholar
• Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H, et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun. 2012;3:883. doi:10.1038/ncomms1892. PMID:22673910.
   PubMed Web of Science ®Google Scholar
• Hu J, Li G, Zhang P, Zhuang X, Hu G. A CD44v+ subpopulation of breast cancer stem-like cells with enhanced lung metastasis capacity. Cell Death Dis. 2017;8(3):e2679. doi:10.1038/cddis.2017.72. PMID:28300837.
   PubMedGoogle Scholar
• Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17(5):548–58. doi:10.1016/j.ceb.2005.08.001. PMID:16098727.
   PubMed Web of Science ®Google Scholar
• Nigam A. Breast cancer stem cells, pathways and therapeutic perspectives 2011. Indian J Surg. 2013;75(3):170–80. doi:10.1007/s12262-012-0616-3. PMID:24426422.
   PubMed Web of Science ®Google Scholar
• Barolo S, Posakony JW. Three habits of highly effective signaling pathways: principles of transcriptional control by developmental cell signaling. Genes Dev. 2002;16(10):1167–81. doi:10.1101/gad.976502. PMID:12023297.
   PubMed Web of Science ®Google Scholar
• Garcia A, JJ Kandel. Notch: a key regulator of tumor angiogenesis and metastasis. Histol Histopathol. 2012;27(2):151–6. PMID:22207549.
   PubMed Web of Science ®Google Scholar
• Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, Bundred NJ, Clarke RB. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 2010;70(2):709–18. doi:10.1158/0008-5472.CAN-09-1681. PMID:20068161.
   PubMed Web of Science ®Google Scholar
• Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004;6(6):R605–15. doi:10.1186/bcr920. PMID:15535842.
   PubMed Web of Science ®Google Scholar
• Sansone P, Storci G, Giovannini C, Pandolfi S, Pianetti S, Taffurelli M, Santini D, Ceccarelli C, Chieco P, Bonafé M. p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells. 2007;25(3):807–15. doi:10.1634/stemcells.2006-0442. PMID:17158237.
   PubMed Web of Science ®Google Scholar
• Pal D, Kolluru V, Chandrasekaran B, Baby BV, Aman M, Suman S, Sirimulla S, Sanders MA, Alatassi H, Ankem MK, et al. Targeting aberrant expression of Notch-1 in ALDH+ cancer stem cells in breast cancer. Mol Carcinog. 2017;56(3):1127–1136.
   Google Scholar
• Suman S, Das TP, Damodaran C. Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells. Br J Cancer. 2013;109(10):2587–96. doi:10.1038/bjc.2013.642. PMID:24129237.
   PubMed Web of Science ®Google Scholar
• McGovern M, Voutev R, Maciejowski J, Corsi AK, Hubbard EJ. A “latent niche” mechanism for tumor initiation. Proc Natl Acad Sci U S A. 2009;106(28):11617–22. doi:10.1073/pnas.0903768106. PMID:19564624.
   PubMed Web of Science ®Google Scholar
• Chen W, Cao G, Yuan X, Zhang X, Zhang Q, Zhu Y, Dong Z, Zhang S. Notch-1 knockdown suppresses proliferation, migration and metastasis of salivary adenoid cystic carcinoma cells. J Transl Med. 2015;13:167. doi:10.1186/s12967-015-0520-2. PMID:25990317.
   PubMed Web of Science ®Google Scholar
• Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev. 2007;17(1):45–51. doi:10.1016/j.gde.2006.12.007. PMID:17208432.
   PubMed Web of Science ®Google Scholar
• MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9–26. doi:10.1016/j.devcel.2009.06.016. PMID:19619488.
   PubMed Web of Science ®Google Scholar
• Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010;176(6):2911–20. doi:10.2353/ajpath.2010.091125. PMID:20395444.
   PubMed Web of Science ®Google Scholar
• Lopez-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, Musgrove EA, Sutherland RL, O'Toole SA, et al. Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2010;19(1):301–9. doi:10.1158/1055-9965.EPI-09-0741. PMID:20056651.
   PubMed Web of Science ®Google Scholar
• Geyer FC, et al. beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol. 2011;24(2):209–31. doi:10.1038/modpathol.2010.205. PMID:21076461.
   PubMed Web of Science ®Google Scholar
• Lindvall C, Zylstra CR, Evans N, West RA, Dykema K, Furge KA, Williams BO. The Wnt co-receptor Lrp6 is required for normal mouse mammary gland development. PLoS One. 2009;4(6):e5813. doi:10.1371/journal.pone.0005813. PMID:19503830.
   PubMed Web of Science ®Google Scholar
• Liu CC, Prior J, Piwnica-Worms D, Bu G. LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci U S A. 2010;107(11):5136–41. doi:10.1073/pnas.0911220107. PMID:20194742.
   PubMed Web of Science ®Google Scholar
• Nusse R. Wnt signaling and stem cell control. Cell Res. 2008;18(5):523–7. doi:10.1038/cr.2008.47. PMID:18392048.
   PubMed Web of Science ®Google Scholar
• Pires BR, DE Amorim ÍS, Souza LD, Rodrigues JA, Mencalha AL. Targeting cellular signaling pathways in breast cancer stem cells and its implication for cancer treatment. Anticancer Res. 2016. 36(11):5681–91. doi:10.21873/anticanres.11151. PMID:27793889.
   PubMed Web of Science ®Google Scholar
• Dey N, Barwick BG, Moreno CS, Ordanic-Kodani M, Chen Z, Oprea-Ilies G, Tang W, Catzavelos C, Kerstann KF, Sledge GW, Jr, et al. Wnt signaling in triple negative breast cancer is associated with metastasis. BMC Cancer. 2013;13:537. doi:10.1186/1471-2407-13-537. PMID:24209998.
   PubMed Web of Science ®Google Scholar
• DiMeo TA, Anderson K, Phadke P, Fan C, Perou CM, Naber S, Kuperwasser C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 2009;69(13):5364–73. doi:10.1158/0008-5472.CAN-08-4135. PMID:19549913.
   PubMed Web of Science ®Google Scholar
• Klauzinska M, Baljinnyam B, Raafat A, Rodriguez-Canales J, Strizzi L, Greer YE, Rubin JS, Callahan R. Rspo2/Int7 regulates invasiveness and tumorigenic properties of mammary epithelial cells. J Cell Physiol. 2012;227(5):1960–71. doi:10.1002/jcp.22924. PMID:21732367.
   PubMed Web of Science ®Google Scholar
• Zhou XL, Qin XR, Zhang XD, Ye LH. Downregulation of Dickkopf-1 is responsible for high proliferation of breast cancer cells via losing control of Wnt/beta-catenin signaling. Acta Pharmacol Sin. 2010;31(2):202–10. doi:10.1038/aps.2009.200. PMID:20139903.
   PubMed Web of Science ®Google Scholar
• Brennan KR, Brown AM. Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2004;9(2):119–31. doi:10.1023/B:JOMG.0000037157.94207.33. PMID:15300008.
   PubMed Web of Science ®Google Scholar
• Zhang K, Zhang J, Han L, Pu P, Kang C. Wnt/beta-catenin signaling in glioma. J Neuroimmune Pharmacol. 2012;7(4):740–9. doi:10.1007/s11481-012-9359-y. PMID:22454041.
   PubMed Web of Science ®Google Scholar
• Zhuang X, Zhang H, Li X, Li X, Cong M, Peng F, Yu J, Zhang X, Yang Q, Hu G. Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1. Nat Cell Biol. 2017;19(10):1274–85. doi:10.1038/ncb3613. PMID:28892080.
   PubMed Web of Science ®Google Scholar
• Benhaj K, Akcali KC, Ozturk M. Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncol Rep. 2006;15(3):701–7. PMID:16465433.
   PubMed Web of Science ®Google Scholar
• Leris AC, Roberts TR, Jiang WG, Newbold RF, Mokbel K. WNT5A expression in human breast cancer. Anticancer Res. 2005;25(2A):731–4. PMID:15868903.
   PubMed Web of Science ®Google Scholar
• Jiang W, Crossman DK, Mitchell EH, Sohn P, Crowley MR, Serra R. WNT5A inhibits metastasis and alters splicing of Cd44 in breast cancer cells. PLoS One. 2013;8(3):e58329. doi:10.1371/journal.pone.0058329. PMID:23484019.
   PubMed Web of Science ®Google Scholar
• Trifa F, Karray-Chouayekh S, Jmal E, Jmaa ZB, Khabir A, Sellami-Boudawara T, Frikha M, Daoud J, Mokdad-Gargouri R. Loss of WIF-1 and Wnt5a expression is related to aggressiveness of sporadic breast cancer in Tunisian patients. Tumour Biol. 2013;34(3):1625–33. doi:10.1007/s13277-013-0694-2. PMID:23417837.
   PubMedGoogle Scholar
• Zhong Z, Shan M, Wang J, Liu T, Shi Q, Pang D. Decreased Wnt5a expression is a poor prognostic factor in triple-negative breast cancer. Med Sci Monit. 2016;22:1–7. doi:10.12659/MSM.894821. PMID:26721633.
   PubMed Web of Science ®Google Scholar
• Borcherding N, Kusner D, Kolb R, Xie Q, Li W, Yuan F, Velez G, Askeland R, Weigel RJ, Zhang W. Paracrine WNT5A signaling inhibits expansion of tumor-initiating cells. Cancer Res. 2015;75(10):1972–82. doi:10.1158/0008-5472.CAN-14-2761. PMID:25769722.
   PubMed Web of Science ®Google Scholar
• Jonsson M, Andersson T. Repression of Wnt-5a impairs DDR1 phosphorylation and modifies adhesion and migration of mammary cells. J Cell Sci. 2001;114(Pt 11):2043–53. PMID:11493640.
   PubMed Web of Science ®Google Scholar
• Medrek C, Landberg G, Andersson T, Leandersson K. Wnt-5a-CKI{alpha} signaling promotes {beta}-catenin/E-cadherin complex formation and intercellular adhesion in human breast epithelial cells. J Biol Chem. 2009;284(16):10968–79. doi:10.1074/jbc.M804923200. PMID:19244247.
   PubMed Web of Science ®Google Scholar
• Jonsson M, Dejmek J, Bendahl PO, Andersson T. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res. 2002;62(2):409–16. PMID:11809689.
   PubMed Web of Science ®Google Scholar
• Shi J, Wang Y, Zeng L, Wu Y, Deng J, Zhang Q, Lin Y, Li J, Kang T, Tao M, et al. Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell. 2014;25(2):210–25. doi:10.1016/j.ccr.2014.01.028. PMID:24525235.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Shen T, Liu J, Zheng J, Zhang Y, Xu R, Sun C, Du J, Chen Y, Gu L. Rab35 is required for Wnt5a/Dvl2-induced Rac1 activation and cell migration in MCF-7 breast cancer cells. Cell Signal. 2013;25(5):1075–85. doi:10.1016/j.cellsig.2013.01.015. PMID:23353182.
   PubMed Web of Science ®Google Scholar
• Han B, et al. FOXC1-induced non-canonical WNT5A-MMP7 signaling regulates invasiveness in triple-negative breast cancer. Oncogene. 2017.
   Web of Science ®Google Scholar
• Flemban A, Qualtrough D. The potential role of hedgehog signaling in the Luminal/Basal Phenotype of breast epithelia and in breast cancer invasion and metastasis. Cancers (Basel). 2015;7(3):1863–84. doi:10.3390/cancers7030866. PMID:26389956.
   PubMed Web of Science ®Google Scholar
• Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature. 2009;458(7239):776–9. doi:10.1038/nature07737. PMID:19169242.
   PubMed Web of Science ®Google Scholar
• Santini R, Vinci MC, Pandolfi S, Penachioni JY, Montagnani V, Olivito B, Gattai R, Pimpinelli N, Gerlini G, Borgognoni L, et al. Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells. Stem Cells. 2012;30(9):1808–18. doi:10.1002/stem.1160. PMID:22730244.
   PubMed Web of Science ®Google Scholar
• Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P, Ruiz i Altaba A. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med. 2009;1(6–7):338–51. doi:10.1002/emmm.200900039. PMID:20049737.
   PubMed Web of Science ®Google Scholar
• Hui M, Cazet A, Nair R, Watkins DN, O'Toole SA, Swarbrick A. The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. Breast Cancer Res. 2013;15(2):203. doi:10.1186/bcr3401. PMID:23547970.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Frolova N, Sadlonova A, Novak Z, Steg A, Page GP, Welch DR, Lobo-Ruppert SM, Ruppert JM, Johnson MR, et al. Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther. 2006;5(6):674–83. doi:10.4161/cbt.5.6.2906. PMID:16855373.
   PubMed Web of Science ®Google Scholar
• Thomas ZI, Gibson W, Sexton JZ, Aird KM, Ingram SM, Aldrich A, Lyerly HK, Devi GR, Williams KP. Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration. Br J Cancer. 2011;104(10):1575–86. doi:10.1038/bjc.2011.133. PMID:21505458.
   PubMed Web of Science ®Google Scholar
• O'Toole SA, Machalek DA, Shearer RF, Millar EK, Nair R, Schofield P, McLeod D, Cooper CL, McNeil CM, McFarland A, et al. Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res. 2011;71(11):4002–14. doi:10.1158/0008-5472.CAN-10-3738. PMID:21632555.
   PubMed Web of Science ®Google Scholar
• Inaguma S, Riku M, Ito H, Tsunoda T, Ikeda H, Kasai K. GLI1 orchestrates CXCR4/CXCR7 signaling to enhance migration and metastasis of breast cancer cells. Oncotarget. 2015;6(32):33648–57. doi:10.18632/oncotarget.5203. PMID:26413813.
   PubMedGoogle Scholar
• Hayashi H, Kume T. Forkhead transcription factors regulate expression of the chemokine receptor CXCR4 in endothelial cells and CXCL12-induced cell migration. Biochem Biophys Res Commun. 2008;367(3):584–9. doi:10.1016/j.bbrc.2007.12.183. PMID:18187037.
   PubMed Web of Science ®Google Scholar
• Han B, Qu Y, Jin Y, Yu Y, Deng N, Wawrowsky K, Zhang X, Li N, Bose S, Wang Q, et al. FOXC1 activates smoothened-independent hedgehog signaling in basal-like breast cancer. Cell Rep. 2015;13(5):1046–58. doi:10.1016/j.celrep.2015.09.063. PMID:26565916.
   PubMed Web of Science ®Google Scholar
• Zuo HD, Wu Yao W. The role and the potential regulatory pathways of high expression of forkhead box C1 in promoting tumor growth and metastasis of basal-like breast cancer. J BUON. 2016;21(4):818–25. PMID:27685901.
   PubMed Web of Science ®Google Scholar
• Liu J, Chen S, Wang W, Ning BF, Chen F, Shen W, Ding J, Chen W, Xie WF, Zhang X. Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-beta pathways. Cancer Lett. 2016;379(1):49–59. doi:10.1016/j.canlet.2016.05.022. PMID:27216982.
   PubMed Web of Science ®Google Scholar
• Zardawi SJ, O'Toole SA, Sutherland RL, Musgrove EA. Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol Histopathol. 2009;24(3):385–98. PMID:19130408.
   PubMed Web of Science ®Google Scholar
• Salem ML, El-Badawy AS, Li Z. Immunobiology and signaling pathways of cancer stem cells: implication for cancer therapy. Cytotechnology. 2015;67(5):749–59. doi:10.1007/s10616-014-9830-0. PMID:25516358.
   PubMed Web of Science ®Google Scholar
• Arnold KM, Pohlig RT, Sims-Mourtada J. Co-activation of Hedgehog and Wnt signaling pathways is associated with poor outcomes in triple negative breast cancer. Oncol Lett. 2017;14(5):5285–92. PMID:29142600.
   PubMed Web of Science ®Google Scholar
• Okuhashi Y, Itoh M, Tohda S. Hedgehog stimulation suppresses clonogenicity and activates NOTCH signalling in T-lymphoblastic Leukaemia Jurkat cells. Anticancer Res. 2017;37(9):5005–9. PMID:28870926.
   PubMed Web of Science ®Google Scholar
• Maeda O, Kondo M, Fujita T, Usami N, Fukui T, Shimokata K, Ando T, Goto H, Sekido Y. Enhancement of GLI1-transcriptional activity by beta-catenin in human cancer cells. Oncol Rep. 2006;16(1):91–6. PMID:16786128.
   PubMed Web of Science ®Google Scholar
• Kikuchi I, Takahashi-Kanemitsu A, Sakiyama N, Tang C, Tang PJ, Noda S, Nakao K, Kassai H, Sato T, Aiba A, et al. Dephosphorylated parafibromin is a transcriptional coactivator of the Wnt/Hedgehog/Notch pathways. Nat Commun. 2016;7:12887. doi:10.1038/ncomms12887. PMID:27650679.
   PubMed Web of Science ®Google Scholar
• Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 2000;18:217–42. doi:10.1146/annurev.immunol.18.1.217. PMID:10837058.
   PubMed Web of Science ®Google Scholar
• Murphy PM, Baggiolini M, Charo IF, Hébert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev. 2000;52(1):145–76. PMID:10699158.
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12(2):121–7. doi:10.1016/S1074-7613(00)80165-X. PMID:10714678.
   PubMed Web of Science ®Google Scholar
• Locati M, Otero K, Schioppa T, Signorelli P, Perrier P, Baviera S, Sozzani S, Mantovani A. The chemokine system: tuning and shaping by regulation of receptor expression and coupling in polarized responses. Allergy. 2002. 57(11):972–82. doi:10.1034/j.1398-9995.2002.02166.x. PMID:12358993.
   PubMed Web of Science ®Google Scholar
• Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol. 2004;22:891–928. doi:10.1146/annurev.immunol.22.012703.104543. PMID:15032599.
   PubMed Web of Science ®Google Scholar
• Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 2007;25:787–820. doi:10.1146/annurev.immunol.24.021605.090529. PMID:17291188.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45. doi:10.1016/S0140-6736(00)04046-0. PMID:11229684.
   PubMed Web of Science ®Google Scholar
• Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540–50. doi:10.1038/nrc1388. PMID:15229479.
   PubMed Web of Science ®Google Scholar
• Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313–26. doi:10.1089/jir.2008.0027. PMID:19441883.
   PubMed Web of Science ®Google Scholar
• Maru Y. The lung metastatic niche. J Mol Med (Berl). 2015;93(11):1185–92. doi:10.1007/s00109-015-1355-2. PMID:26489606.
   PubMed Web of Science ®Google Scholar
• Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012;150(1):165–78. doi:10.1016/j.cell.2012.04.042. PMID:22770218.
   PubMed Web of Science ®Google Scholar
• Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50–6. doi:10.1038/35065016. PMID:11242036.
   PubMed Web of Science ®Google Scholar
• Mukherjee D, Zhao J. The Role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res. 2013;3(1):46–57. PMID:23359227.
   PubMed Web of Science ®Google Scholar
• Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005;23(7):879–94. doi:10.1634/stemcells.2004-0342. PMID:15888687.
   PubMed Web of Science ®Google Scholar
• Atretkhany KN, et al. Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment. Pharmacol Ther. 2016;168:98–112. doi:10.1016/j.pharmthera.2016.09.011. PMID:27613100.
   PubMed Web of Science ®Google Scholar
• Gong HY, Hu WG, Hu QY, Li XP, Song QB. Radiation-induced pulmonary injury accelerated pulmonary metastasis in a mouse model of breast cancer. Oncol Lett. 2015. 10(6):3613–8. doi:10.3892/ol.2015.3810. PMID:26788178.
   PubMed Web of Science ®Google Scholar
• Chen HW, Du CW, Wei XL, Khoo US, Zhang GJ. Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer. Curr Mol Med. 2013;13(3):410–6. PMID:23331013.
   PubMed Web of Science ®Google Scholar
• Boimel PJ, Smirnova T, Zhou ZN, Wyckoff J, Park H, Coniglio SJ, Qian BZ, Stanley ER, Cox D, Pollard JW, et al. Contribution of CXCL12 secretion to invasion of breast cancer cells. Breast Cancer Res. 2012;14(1):R23. doi:10.1186/bcr3108. PMID:22314082.
   PubMed Web of Science ®Google Scholar
• Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res. 2002;62(24):7203–6. PMID:12499259.
   PubMed Web of Science ®Google Scholar
• Hall JM, Korach KS. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol. 2003;17(5):792–803. doi:10.1210/me.2002-0438. PMID:12586845.
   PubMed Web of Science ®Google Scholar
• Helbig G, Christopherson KW, 2nd, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, Broxmeyer HE, Nakshatri H. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem. 2003;278(24):21631–8. doi:10.1074/jbc.M300609200. PMID:12690099.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Bonecchi R, Locati M. Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunol. 2006;6(12):907–18. doi:10.1038/nri1964. PMID:17124512.
   PubMed Web of Science ®Google Scholar
• Wang J, Ou ZL, Hou YF, Luo JM, Chen Y, Zhou J, Shen ZZ, Ding J, Shao ZM. Duffy antigen receptor for chemokines attenuates breast cancer growth and metastasis: an experiment with nude mice. Zhonghua Yi Xue Za Zhi. 2005;85(29):2033–7. PMID:16313795.
   PubMedGoogle Scholar
• Galzi JL, Hachet-Haas M, Bonnet D, Daubeuf F, Lecat S, Hibert M, Haiech J, Frossard N. Neutralizing endogenous chemokines with small molecules. Principles and potential therapeutic applications. Pharmacol Ther. 2010;126(1):39–55. doi:10.1016/j.pharmthera.2009.12.003. PMID:20117133.
   PubMed Web of Science ®Google Scholar
• Wu FY, Ou ZL, Feng LY, Luo JM, Wang LP, Shen ZZ, Shao ZM. Chemokine decoy receptor d6 plays a negative role in human breast cancer. Mol Cancer Res. 2008;6(8):1276–88. doi:10.1158/1541-7786.MCR-07-2108. PMID:18708360.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010;21(1):27–39. doi:10.1016/j.cytogfr.2009.11.007. PMID:20004131.
   PubMed Web of Science ®Google Scholar
• Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell. 2010;18(6):884–901. doi:10.1016/j.devcel.2010.05.012. PMID:20627072.
   PubMed Web of Science ®Google Scholar
• Polyak K, Kalluri R. The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol. 2010;2(11):a003244. doi:10.1101/cshperspect.a003244. PMID:20591988.
   PubMed Web of Science ®Google Scholar
• Ursini-Siegel J, Siegel PM. The influence of the pre-metastatic niche on breast cancer metastasis. Cancer Lett. 2016;380(1):281–8.
   PubMed Web of Science ®Google Scholar
• Soikkeli J, Podlasz P, Yin M, Nummela P, Jahkola T, Virolainen S, Krogerus L, Heikkilä P, von Smitten K, Saksela O, et al. Metastatic outgrowth encompasses COL-I, FN1, and POSTN up-regulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth. Am J Pathol. 2010;177(1):387–403. doi:10.2353/ajpath.2010.090748. PMID:20489157.
   PubMed Web of Science ®Google Scholar
• Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E, Massagué J. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med. 2011;17(7):867–74. doi:10.1038/nm.2379. PMID:21706029.
   PubMed Web of Science ®Google Scholar
• O'Connell JT, Sugimoto H, Cooke VG, MacDonald BA, Mehta AI, LeBleu VS, Dewar R, Rocha RM, Brentani RR, Resnick MB, et al. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci U S A. 2011;108(38):16002–7. doi:10.1073/pnas.1109493108. PMID:21911392.
   PubMed Web of Science ®Google Scholar
• Malanchi I, Santamaria-Martine A, Susanto E, Peng H, Lehr HA, Delaloye JF, Huelsken J. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2012;481(7379):85–9. doi:10.1038/nature10694.
   Web of Science ®Google Scholar
• Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R, Sadik H, Argani P, Wagner P, Vahdat LT, et al. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res. 2012;72(6):1384–94. doi:10.1158/0008-5472.CAN-11-2905. PMID:22282653.
   PubMed Web of Science ®Google Scholar
• Sharma R, Sharma R, Khaket TP, Dutta C, Chakraborty B, Mukherjee TK. Breast cancer metastasis: Putative therapeutic role of vascular cell adhesion molecule-1. Cell Oncol (Dordr). 2017;40(3):199–208. doi:10.1007/s13402-017-0324-x. PMID:28534212.
   PubMed Web of Science ®Google Scholar
• Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massagué J. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436(7050):518–24. doi:10.1038/nature03799. PMID:16049480.
   PubMed Web of Science ®Google Scholar
• Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, Massagué J. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133(1):66–77. doi:10.1016/j.cell.2008.01.046. PMID:18394990.
   PubMed Web of Science ®Google Scholar
• Hembruff SL, Jokar I, Yang L, Cheng N. Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms. Neoplasia. 2010;12(5):425–33. doi:10.1593/neo.10200. PMID:20454514.
   PubMed Web of Science ®Google Scholar
• Drabsch Y, ten Dijke P. TGF-beta signaling in breast cancer cell invasion and bone metastasis. J Mammary Gland Biol Neoplasia. 2011;16(2):97–108. doi:10.1007/s10911-011-9217-1. PMID:21494783.
   PubMed Web of Science ®Google Scholar
• Fazilaty H, Gardaneh M, Bahrami T, Salmaninejad A, Behnam B. Crosstalk between breast cancer stem cells and metastatic niche: emerging molecular metastasis pathway? Tumour Biol. 2013;34(4):2019–30. doi:10.1007/s13277-013-0831-y. PMID:23686802.
   PubMedGoogle Scholar
• Ye Y, Liu S, Wu C, Sun Z. TGFbeta modulates inflammatory cytokines and growth factors to create premetastatic microenvironment and stimulate lung metastasis. J Mol Histol. 2015;46(4–5):365–75. doi:10.1007/s10735-015-9633-4. PMID:26208571.
   PubMed Web of Science ®Google Scholar
• Park CY, Min KN, Son JY, Park SY, Nam JS, Kim DK, Sheen YY. An novel inhibitor of TGF-beta type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition. Cancer Lett. 2014;351(1):72–80. doi:10.1016/j.canlet.2014.05.006. PMID:24887560.
   PubMed Web of Science ®Google Scholar
• Son JY, Park SY, Kim SJ, Lee SJ, Park SA, Kim MJ, Kim SW, Kim DK, Nam JS, Sheen YY. EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis. Mol Cancer Ther. 2014;13(7):1704–16. doi:10.1158/1535-7163.MCT-13-0903. PMID:24817629.
   PubMed Web of Science ®Google Scholar
• Yan HH, Pickup M, Pang Y, Gorska AE, Li Z, Chytil A, Geng Y, Gray JW, Moses HL, Yang L. Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res. 2010;70(15):6139–49. doi:10.1158/0008-5472.CAN-10-0706. PMID:20631080.
   PubMed Web of Science ®Google Scholar
• Pekarek LA, Starr BA, Toledano AY, Schreiber H. Inhibition of tumor growth by elimination of granulocytes. J Exp Med. 1995;181(1):435–40. doi:10.1084/jem.181.1.435. PMID:7807024.
   PubMed Web of Science ®Google Scholar
• Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Verstegen NJM, Ciampricotti M, Hawinkels LJAC, Jonkers J, et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522(7556):345–8. doi:10.1038/nature14282. PMID:25822788.
   PubMed Web of Science ®Google Scholar
• Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol. 2006;8(12):1369–75. doi:10.1038/ncb1507. PMID:17128264.
   PubMed Web of Science ®Google Scholar
• Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, Le QT, Giaccia AJ. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2009;15(1):35–44. doi:10.1016/j.ccr.2008.11.012. PMID:19111879.
   PubMed Web of Science ®Google Scholar
• Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820–7. doi:10.1038/nature04186. PMID:16341007.
   PubMed Web of Science ®Google Scholar
• Yu PF, Huang Y, Han YY, Lin LY, Sun WH, Rabson AB, Wang Y, Shi YF. TNFalpha-activated mesenchymal stromal cells promote breast cancer metastasis by recruiting CXCR2+ neutrophils. Oncogene. 2016;36(4):482–490.
   Google Scholar
• Acharyya S, Massague J. Arresting supporters: targeting neutrophils in metastasis. Cell Res. 2016;26(3):273–4. doi:10.1038/cr.2016.17. PMID:26823207.
   PubMed Web of Science ®Google Scholar
• Wculek SK, Malanchi I. Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature. 2015;528(7582):413–7. doi:10.1038/nature16140. PMID:26649828.
   PubMed Web of Science ®Google Scholar
• Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4(1):71–8. doi:10.1038/nrc1256. PMID:14708027.
   PubMed Web of Science ®Google Scholar
• Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222–5. doi:10.1038/nature10138. PMID:21654748.
   PubMed Web of Science ®Google Scholar
• Chen J, Yao Y, Gong C, Yu F, Su S, Chen J, Liu B, Deng H, Wang F, Lin L, et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell. 2011;19(4):541–55. doi:10.1016/j.ccr.2011.02.006. PMID:21481794.
   PubMed Web of Science ®Google Scholar
• Lin X, Chen L, Yao Y, Zhao R, Cui X, Chen J, Hou K, Zhang M, Su F, Chen J, et al. CCL18-mediated down-regulation of miR98 and miR27b promotes breast cancer metastasis. Oncotarget. 2015;6(24):20485–99. doi:10.18632/oncotarget.4107. PMID:26244871.
   PubMedGoogle Scholar
• Chen Q, Zhang XH, Massague J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell. 2011;20(4):538–49. doi:10.1016/j.ccr.2011.08.025. PMID:22014578.
   PubMed Web of Science ®Google Scholar
• Li XJ, Gangadaran P, Kalimuthu S, Oh JM, Zhu L, Jeong SY, Lee SW, Lee J, Ahn BC. Role of pulmonary macrophages in initiation of lung metastasis in anaplastic thyroid cancer. Int J Cancer. 2016;139(11):2583–92. doi:10.1002/ijc.30387. PMID:27537102.
   PubMed Web of Science ®Google Scholar
• Cao H, Dan Z, He X, Zhang Z, Yu H, Yin Q, Li Y. Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano. 2016;10(8):7738–48. doi:10.1021/acsnano.6b03148. PMID:27454827.
   PubMed Web of Science ®Google Scholar
• Vadrevu SK, Sharma S, Chintala N, Patel J, Karbowniczek M, Markiewski M. Studying the role of alveolar macrophages in breast cancer metastasis. J Vis Exp. 2016;(112). doi:10.3791/54306. PMID:27403530.
   PubMed Web of Science ®Google Scholar
• Xu K, Tian X, Oh SY, Movassaghi M, Naber SP, Kuperwasser C, Buchsbaum RJ. The fibroblast Tiam1-osteopontin pathway modulates breast cancer invasion and metastasis. Breast Cancer Res. 2016;18(1):14. doi:10.1186/s13058-016-0674-8. PMID:26821678.
   PubMedGoogle Scholar
• Kim HM, Jung WH, Koo JS. Expression of cancer-associated fibroblast related proteins in metastatic breast cancer: an immunohistochemical analysis. J Transl Med. 2015;13:222. doi:10.1186/s12967-015-0587-9. PMID:26163388.
   PubMed Web of Science ®Google Scholar
• Hasebe T. Tumor-stromal interactions in breast tumor progression–significance of histological heterogeneity of tumor-stromal fibroblasts. Expert Opin Ther Targets. 2013;17(4):449–60. doi:10.1517/14728222.2013.757305. PMID:23297753.
   PubMed Web of Science ®Google Scholar
• Takai K, Le A, Weaver VM, Werb Z. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget. 2016;7(50):82889–901. doi:10.18632/oncotarget.12658. PMID:27756881.
   PubMedGoogle Scholar
• Ci Y, Qiao J, Han M. Molecular mechanisms and metabolomics of natural polyphenols interfering with breast cancer metastasis. Molecules. 2016;21(12):E1634. doi:10.3390/molecules21121634. PMID:27999314.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1–22. doi:10.1007/978-0-387-74039-3_1. PMID:17993229.
   PubMed Web of Science ®Google Scholar
• Jang GB, Hong IS, Kim RJ, Lee SY, Park SJ, Lee ES, Park JH, Yun CH, Chung JU, Lee KJ, et al. Wnt/beta-Catenin small-molecule inhibitor CWP232228 preferentially inhibits the growth of breast cancer stem-like cells. Cancer Res. 2015;75(8):1691–702. doi:10.1158/0008-5472.CAN-14-2041. PMID:25660951.
   PubMed Web of Science ®Google Scholar
• Kurebayashi J, Koike Y, Ohta Y, Saitoh W, Yamashita T, Kanomata N, Moriya T. Anti-cancer stem cell activity of a hedgehog inhibitor GANT61 in estrogen receptor-positive breast cancer cells. Cancer Sci. 2017;108(5):918–30. doi:10.1111/cas.13205. PMID:28211214.
   PubMed Web of Science ®Google Scholar
• Koike Y, Ohta Y, Saitoh W, Yamashita T, Kanomata N, Moriya T, Kurebayashi J. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells. Breast Cancer. 2017;24(5):683–93. doi:10.1007/s12282-017-0757-0. PMID:28144905.
   PubMed Web of Science ®Google Scholar
• Huebschman ML, Lane NL, Liu H, Sarode VR, Devlin JL, Frenkel EP. Molecular heterogeneity in adjacent cells in triple-negative breast cancer. Breast Cancer (Dove Med Press). 2015;7:231–7. PMID:26316815.
   PubMed Web of Science ®Google Scholar
• Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9(5):R65. doi:10.1186/bcr1771. PMID:17910759.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67. doi:10.1172/JCI45014. PMID:21633166.
   PubMed Web of Science ®Google Scholar
• Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, Geyer FC, van Kouwenhove M, Kreike B, Mackay A, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010;29(14):2013–23. doi:10.1038/onc.2009.489. PMID:20101236.
   PubMed Web of Science ®Google Scholar
• Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dadbin A, Lee J, Saso H, Smith PD, Dalby KN, Ueno NT. MEK inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents lung metastasis in a triple-negative breast cancer xenograft model. Mol Cancer Ther. 2015. 14(12):2773–81. doi:10.1158/1535-7163.MCT-15-0243. PMID:26384399.
   PubMed Web of Science ®Google Scholar
• Citterio C, Menacho-Márquez M, García-Escudero R, Larive RM, Barreiro O, Sánchez-Madrid F, Paramio JM, Bustelo XR. The rho exchange factors vav2 and vav3 control a lung metastasis-specific transcriptional program in breast cancer cells. Sci Signal. 2012;5(244):ra71. doi:10.1126/scisignal.2002962. PMID:23033540.
   PubMed Web of Science ®Google Scholar
• Emens LA. Chemotherapy and tumor immunity: an unexpected collaboration. Front Biosci. 2008;13:249–57. doi:10.2741/2675. PMID:17981543.
   PubMed Web of Science ®Google Scholar
• Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 2005. 65(18):8059–64. doi:10.1158/0008-5472.CAN-05-1797. PMID:16166275.
   PubMed Web of Science ®Google Scholar
• Finn OJ. Cancer immunology. N Engl J Med. 2008;358(25):2704–15. doi:10.1056/NEJMra072739. PMID:18565863.
   PubMed Web of Science ®Google Scholar
• Varn FS, Mullins DW, Arias-Pulido H, Fiering S, Cheng C. Adaptive immunity programmes in breast cancer. Immunology. 2016;150(1):25–34. PMID:27564847.
   PubMedGoogle Scholar
• Gray MJ, Gong J, Hatch MM, Nguyen V, Hughes CC, Hutchins JT, Freimark BD. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. Breast Cancer Res. 2016;18(1):50. doi:10.1186/s13058-016-0708-2. PMID:27169467.
   PubMedGoogle Scholar